Humoral immunity after Pfizer/BioNTech BNT162b2 vaccine in healthcare workers of ASL Roma 2 (Italy)


https://doi.org/10.4081/mm.2021.9695
Vol. 36 No. 2 (2021)
Submitted: 19 February 2021
Accepted: 29 April 2021
Published: 28 October 2021
Vaccine, Sars-CoV-2, COVID-19, coronavirus, humoral immunity
Abstract Views: 460
PDF: 178
HTML: 3
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Eliana Giberna
    e.giberna@outlook.it
    Unit of Microbiology and Virology, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Tiziana Guastafierro Unit of Clinical Pathology and Biochemistry, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Natalia Ciaffi Unit of Microbiology and Virology, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Elena Nebuloso Unit of Microbiology and Virology, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Stefania Piccoli Unit of Microbiology and Virology, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Mattia Serao Unit of Pneumology, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Giuseppina Gioffrè Unit of Pneumology, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Stefania Campitelli Unit of Coordination of Vaccinal Activities, Sandro Pertini Hospital Asl Roma 2, Rome, Israel.
  • Maria Grazia Colace Unit of Clinical Pathology and Biochemistry, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Maria Carmela Cava Unit of Microbiology and Virology, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.
  • Maria De Cristofaro Unit of Microbiology and Virology, Sandro Pertini Hospital Asl Roma 2, Rome, Italy.

The Unit (COU) of Microbiology and Virology of Sandro Pertini Hospital began monitoring the immune response on a cohort of healthcare operators who received the Pfizer/BioNTech BNT162b2 vaccine. Three different tests for the detection of antibodies against SARS-CoV-2 were used showing 100% of seroconversion after 28 days from the first dose.


Giberna, E., Guastafierro, T., Ciaffi, N. ., Nebuloso, E., Piccoli, S., Serao, M., Gioffrè, G., Campitelli, S., Colace, M. G., Cava, M. C., & De Cristofaro, M. . (2021). Humoral immunity after Pfizer/BioNTech BNT162b2 vaccine in healthcare workers of ASL Roma 2 (Italy). Microbiologia Medica, 36(2). https://doi.org/10.4081/mm.2021.9695

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC